NR4A1 and breast cancer: Thus, 17β-estradiol can activate the ER signaling which is crucial for breast cancer progression, but ICI 182780, which is a derivative of 17β-estradiol with an added alkyl-sulfinyl moiety that degrades ER and affects its ligand-independent functions, is used for the treatment of hormone receptor positive metastatic breast cancer[32].